Loading
Life sciences · Journal article
International Journal of Molecular Sciences · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are highly prevalent chronic disorders with increasing global burdens that frequently coexist and share common risk factors, including obesity, aging and chronic low-grade inflammation. This narrative review aims to summarize current evidence regarding the epidemiological, clinical and molecular links between T2DM and OA and to highlight potential therapeutic implications. Growing evidence suggests that T2DM contributes to OA development and progression through multiple interconnected mechanisms. These include advanced glycation end-product (AGE) accumulation, oxidative stress, chronic inflammation, extracellular matrix degradation, impaired autophagy, ferroptosis, mesenchymal stem cell dysfunction and microvascular impairment within joint tissues. In addition, shared genetic and molecular pathways, including AGE–RAGE, IL-17, PI3K/Akt/mTOR and LGR6/Wnt/β-catenin/NRF2 signaling, further support a biological connection between the two diseases. Clinically, T2DM is associated with increased OA severity, enhanced pain sensitization, accelerated disease progression and higher rates of joint arthroplasty. Emerging evidence also suggests that antidiabetic agents, particularly metformin and glucagon-like peptide 1 receptor agonists, may exert disease-modifying effects through anti-inflammatory, metabolic and chondroprotective mechanisms. Overall, T2DM and OA should be regarded as interconnected metabolic-inflammatory disorders. Improved understanding of their shared mechanisms may facilitate earlier intervention, therapeutic repurposing and integrated multidisciplinary management strategies to reduce disease burden and improve patient outcomes.